Coherus Oncology, Inc.
CHRS
$1.42
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 47.99% | 59.81% | -66.28% | -82.30% | -86.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.99% | 59.81% | -66.28% | -82.30% | -86.05% |
| Cost of Revenue | 50.64% | 58.29% | -86.17% | -90.44% | -93.08% |
| Gross Profit | 46.78% | 60.56% | 25.47% | -65.43% | -73.98% |
| SG&A Expenses | -16.44% | -16.52% | -21.35% | -26.98% | -33.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.42% | 1.47% | -32.01% | -41.68% | -49.23% |
| Operating Income | 5.73% | 6.67% | 13.78% | 3.41% | 3.92% |
| Income Before Tax | 11.88% | 15.45% | 26.89% | 23.34% | 15.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.88% | 15.45% | 26.89% | 23.22% | 14.88% |
| Earnings from Discontinued Operations | 452.16% | 43.28% | 35.30% | 71.82% | -61.97% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 242.26% | 489.41% | 34,538.00% | 712.65% | -120.85% |
| EBIT | 5.73% | 6.67% | 13.78% | 3.41% | 3.92% |
| EBITDA | 5.27% | 6.13% | 13.53% | 3.49% | 4.28% |
| EPS Basic | 246.99% | 445.44% | 17,176.92% | 582.47% | -62.18% |
| Normalized Basic EPS | 12.82% | 9.80% | 20.22% | 16.46% | 22.42% |
| EPS Diluted | 246.99% | 445.44% | 10,425.58% | 568.57% | -60.00% |
| Normalized Diluted EPS | 12.82% | 9.80% | 20.22% | 16.46% | 22.42% |
| Average Basic Shares Outstanding | 6.02% | 2.26% | 2.05% | 5.90% | 12.72% |
| Average Diluted Shares Outstanding | 6.02% | 2.26% | 2.05% | 5.90% | 12.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |